Investigations of cAMP-dependent brain-barrier permeability in choroid plexus
脉络丛 cAMP 依赖性脑屏障通透性的研究
基本信息
- 批准号:10753098
- 负责人:
- 金额:$ 7.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-08-30
- 项目状态:未结题
- 来源:
- 关键词:AdultAgonistApicalBiochemicalBiological AssayBiologyBloodBlood - brain barrier anatomyBlood CirculationBlood-Borne PathogensBostonBrainBrain DiseasesBrain Hypoxia-IschemiaCalciumCell NucleusCellsCentral Nervous SystemCerebral VentriclesCerebrospinal FluidChoroid Plexus EpitheliumCollaborationsCoupledCyclic AMPCyclic AMP ReceptorsCyclic AMP-Dependent Protein KinasesDataDevelopmentDextransDiseaseElectron MicroscopyEndothelial CellsEndotheliumEnvironmentEpilepsyEpithelial CellsExposure toFellowshipFluorescent DyesG-Protein-Coupled ReceptorsGlutamatesGoalsHealthImageImaging TechniquesImaging technologyIn VitroIndividualIntravenousInvestigationLaboratoriesLigandsLinkMapsMeasuresMediatingMental DepressionMental disordersMentorsMethodsMolecularMolecular WeightMusNeurogliaNeurologicNeurotransmittersPediatric HospitalsPeripheralPeripheral Nervous SystemPermeabilityPlayPopulationPredispositionPreparationProcessProductionPropertyProtocols documentationPublicationsRegulationReporterResearchResolutionRoleSchizophreniaSignal TransductionSourceStainsStructure of choroid plexusSurfaceTechniquesTestingTherapeutic InterventionTight JunctionsTissuesTrainingTraumatic Brain InjuryVascular Endothelial CellVascularizationVisualizationapical membraneawakebench to bedsideblood cerebrospinal fluid barrierbrain tissuecareercell typeexperimental studyimaging modalityimprovedin vivoin vivo imagingin vivo optical imagingin vivo two-photon imagingintravenous injectionlateral ventriclemetabotropic glutamate receptor 8nervous system disorderneuroprotectionnovel strategiesreceptorselective expressionsensortooltwo-photon
项目摘要
PROJECT SUMMARY
The choroid plexus (ChP) comprises a network of cells that form a critical brain barrier that can mediate
secondary damage in certain brain disorders and trauma. The Lehtinen lab has developed a suite of tools to
study the ChP across development ex vivo and in vivo. This project applies imaging technology to study blood-
CSF barrier permeability regulation at the cellular level. Our overarching hypothesis is that the intracellular
messenger cAMP regulates endothelial tight junctions between ChP epithelial cells and thereby blood-CSF
barrier integrity as it does in the nearby blood-brain barrier (BBB). The main effectors of cAMP, PKA and Epac,
regulate endothelial tight junction redistribution and barrier permeability. Gi/o-linked G-Protein Coupled
Receptors (GPCRs) are strong upstream regulators of cAMP. The Lehtinen laboratory's single nucleus
sequencing data suggest that ChP epithelial cells selectively and developmentally express mGlur8, which via
Gαi, activation in other brain tissues inhibits cAMP production. To elucidate mechanisms of neurotransmitter
alteration of the blood-CSF barrier we will study the cellular mechanisms of neurotransmitter-activated GPCR-
cAMP signaling in ChP epithelial cells. The Lehtinen lab, in collaboration with co-sponsor Mark Andermann's
lab, recently established a protocol for ex vivo and in vivo imaging of ChP structure and function based on
using fluorescent reporters of calcium activity. I will apply these techniques to reveal how GPCRs modulate
cAMP levels using fluorescent cAMP indicators in ChP explants (Aim 1). In Aim 2 we will use an in vivo
preparation to map the populations of receptors that are accessible to central vs peripheral ligands. Those
located on the apical membrane are in contact with the CSF and those on the basal surface are exposed to the
blood. With functional assays including peripheral delivery of low molecular weight fluorescent dyes, we will
assess the effects of central (CSF) vs peripheral (intravenous) delivered ligands such as mGluR8 agonists on
cAMP and blood-CSF barrier permeability. Together these studies will reveal mechanisms how
neurotransmitters, specifically glutamate, may contribute to blood-CSF barrier integrity in health and disease.
The research and training proposed will take place at Boston Children's Hospital, a world-renowned pediatric
hospital that offers an exceptional research environment and countless opportunities to carry research from
bench to bedside. Importantly, the research proposed will take place under the guidance of Dr. Maria Lehtinen,
an expert in the field of choroid plexus and CSF biology. In addition, Dr. Mark Andermann (co-mentor) is a
leader in in vivo optical imaging techniques. The results from this proposal will result in first-authored
publications and a wealth of preliminary data for a competitive K99/R00 application. This fellowship will provide
the candidate with the opportunity to begin training in choroid plexus biology and make significant scientific
contributions while also helping launch an independent academic career.
项目摘要
脉络丛(ChP)由细胞网络组成,形成关键的脑屏障,可以介导
某些脑部疾病和创伤的继发性损伤。Lehtinen实验室开发了一套工具,
研究离体和体内开发的ChP。该项目应用成像技术研究血液-
细胞水平上的CSF屏障通透性调节。我们的首要假设是细胞内
信使cAMP调节ChP上皮细胞之间的内皮紧密连接,从而调节血液-CSF
屏障完整性,因为它在附近的血脑屏障(BBB)。cAMP、PKA和Epac的主要效应物,
调节内皮紧密连接再分布和屏障通透性。Gi/o连接的G蛋白偶联物
受体(GPCR)是cAMP的强上游调节剂。莱赫蒂宁实验室的单核
测序数据表明,ChP上皮细胞选择性地和发育性地表达mGlur 8,其通过
Gαi在其他脑组织中的激活抑制cAMP的产生。阐明神经递质的作用机制
我们将研究神经递质激活的GPCR的细胞机制,
ChP上皮细胞中的cAMP信号传导。Lehtinen实验室与共同赞助商Mark Andermann合作,
实验室,最近建立了一个协议,离体和体内成像的ChP结构和功能的基础上,
使用钙活性的荧光报告物。我将应用这些技术来揭示GPCR如何调节
使用ChP外植体中的荧光cAMP指示剂的cAMP水平(目的1)。在目标2中,我们将使用体内
制备以绘制可接近中枢配体与外周配体的受体群体。那些
位于顶膜上的细胞与CSF接触,而位于基底表面上的细胞暴露于CSF。
血通过包括低分子量荧光染料的外周递送的功能测定,我们将
评估中枢(CSF)与外周(静脉内)递送的配体如mGluR 8激动剂对
cAMP和血-CSF屏障通透性。这些研究将共同揭示机制,
神经递质,特别是谷氨酸,可能有助于健康和疾病中的血-CSF屏障完整性。
拟议的研究和培训将在波士顿儿童医院进行,这是一家世界知名的儿科医院。
医院提供了一个特殊的研究环境和无数的机会进行研究,从
长凳到床边重要的是,拟议的研究将在Maria Lehtinen博士的指导下进行,
脉络丛和脑脊液生物学领域的专家。此外,Mark Andermann博士(共同导师)是一位
活体光学成像技术的领导者。此提案的结果将导致第一作者
这些数据包括大量的出版物和大量的初步数据,可用于竞争性K99/R 00应用。该奖学金将提供
候选人有机会开始脉络丛生物学培训,
贡献,同时也帮助启动一个独立的学术生涯。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dario Xavier Figueroa Velez其他文献
Dario Xavier Figueroa Velez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dario Xavier Figueroa Velez', 18)}}的其他基金
Dissecting the circuits that support high acuity spatial vision
剖析支持高敏锐度空间视觉的电路
- 批准号:
9401999 - 财政年份:2017
- 资助金额:
$ 7.41万 - 项目类别:
Dissecting the circuits that support high acuity spatial vision
剖析支持高敏锐度空间视觉的电路
- 批准号:
9752625 - 财政年份:2017
- 资助金额:
$ 7.41万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 7.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 7.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别: